| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000028361 |
| Receipt No. | R000032469 |
| Scientific Title | Retrospective investigation of differential features between autoimmune pancreatitis and pancreatic cancer |
| Date of disclosure of the study information | 2017/08/01 |
| Last modified on | 2019/07/24 (Ver. 5) |
| Basic information | ||
| Public title | Retrospective investigation of differential features between autoimmune pancreatitis and pancreatic cancer | |
| Acronym | Retrospective investigation of differential features between AIP and PC | |
| Scientific Title | Retrospective investigation of differential features between autoimmune pancreatitis and pancreatic cancer | |
| Scientific Title:Acronym | Retrospective investigation of differential features between AIP and PC | |
| Region |
|
|
| Condition | ||||
| Condition | Autoimmune pancreatitis (AIP)
Pancreatic cancer (PC: as a comparative disease) |
|||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To clarify diagnostically and histopathologically differential features between autoimmune pancreatitis (AIP) and pancreatic cancer (PC) by the retrospective intercomparison.
- Diagnostic findings are based on CT/MRI mainly and others. - Histopathological findings are delivered from resected specimens. |
| Basic objectives2 | Others |
| Basic objectives -Others | - |
| Trial characteristics_1 | Others |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Diagnostically and histopathologically differential features between AIP and PC
1) Independent evaluation of all imaging data (mainly CT/MRI) and pathological specimens by radiologists and pathologists, respectively, regarding the following items. --Major evaluation items on diagnostic images-- - General findings - Findings inside pancreas - Findings in margin of the lesion - Findings in pancreatic duct --Major evaluation items on histopathological findings-- - Findings in pancreas 2) Evaluation of differential features and similarities between AIP and PC by intercomparison based on the consensus between the radiologists and the pathologists. |
| Key secondary outcomes | |
| Base | |
| Study type | Others,meta-analysis etc |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Pts. diagnosed as AIP or PC
2) Pts. who were performed dynamic MDCT or MRI, followed pancreatic resection within 3 months, during 2005.1 - 2014.12 3) Imaging data of MDCT and/or MRI and histopathological specimens can be provided for central evaluation 4) Diagnostic standard: AIP: Consensus statement by Deshpande V et al. (Modern Pathology 2012) PC: Japanese guideline of medical practice for pancreatic cancer 2013 5) Accept regardless of age and gender |
|||
| Key exclusion criteria | 1) AIP pts. with pre-operative steroid treatment
2) PC pts. with pre-operative chemotherapy or radiation treatment 3) Pts. who were doubly registered 4) Any other pts. who are determined ineligible for this study by investigators |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kanazawa University | ||||||
| Division name | Department of Radiology | ||||||
| Zip code | 920-8641 | ||||||
| Address | 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641 | ||||||
| TEL | +81-76-265-2323 | ||||||
| gabata@med.m.kanazawa-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kanazawa University Hospital | ||||||
| Division name | Department of Radiology | ||||||
| Zip code | 920-8641 | ||||||
| Address | 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641 | ||||||
| TEL | +81-76-265-2323 | ||||||
| Homepage URL | |||||||
| d-inoue@lake.ocn.ne.jp | |||||||
| Sponsor | |
| Institute | Department of Radiology,
Kanazawa University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Bayer Yakuhin Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Independent Ethics Committee of Kanazawa University School of Medicine |
| Address | 13-1, Takara-machi, Kanazawa, Ishikawa |
| Tel | +81-76-265-2100 |
| t-isomu@adm.kanazawa-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 金沢大学大学院医薬保健学総合研究科 内科系医学領域 放射線科学
その他、日本国内およそ10施設が参加予定 About 10 institutions in Japan will participate in this study. Department of Radiology, Kanazawa University |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Observation items
-Patients' background -Items related to MDCT exam a) -Items related to MRI exam a) -Items related to ERCP b) -Items related to FDG-PET b) -Items related to EUS-FNA biopsy b) -Items related to other imaging exams b) -Items related to histopathological Specimens a) Whichever is mandatory b) If available |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032469 |